Update on Management of Type 2 Diabetes for Cardiologists

Qureshi, Mohammed; Gammoh, Emily; Shakil, Jawairia; Robbins, Richard J.

doi:10.14797/mdcj-14-4-273

Cited by 11 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, about 18% of HCPs opined that they would consider addition of a potential therapeutic antidiabetic agent for the treatment of patients with T2DM and CVD only if it has CV benefits, CV neutrality, effect on blood pressure, effect on body weight, glycemic benefit, and low risk of hypoglycemia. This is in line with the previously published update on the management of T2DM for cardiologists where it highlighted that an optimal antidiabetic agent should be able to produce optimal glycemic control, low risk of hypoglycemia, reduce CVD risk, preferably no weight gain and optimal control of blood pressure [28].…”

Section: Discussionsupporting

confidence: 87%

Expert viewpoint on the position of Vildagliptin in a cardiology clinic in Indian clinical settings

Das¹,

Shah²,

Warrier³

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Objective: To analyze the opinion of Indian clinical experts on the current usage patterns of vildagliptin in the treatment of patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Methods: This report summarizes opinions and discussions that occurred during the 36 virtual round table meetings (May 2021 - March 2022) involving 540 healthcare practitioners (HCPs) across India. The collected data were analyzed and categorized into four grades: Level A, very strong (≥80% responses); Level B, strong (≥50-79% responses); Level C, moderate (25-49% responses); Level D, neutral/no consensus (<25% responses). Results: Healthcare practitioners gave opinions for the following; Level A (90.9%): time-in-range (TIR) and glycemic variability are important clinical criteria for selecting antidiabetic therapy in patients with risks of macrovascular complications; Level B (70.8%): vildagliptin gives better TIR and less glycemic variability compared to other dipeptidyl peptidase-4 inhibitors; Level A (90.9%): addition of vildagliptin should be considered in patients with T2DM and established atherosclerotic CVD who have uncontrolled glycemia with metformin plus sodium-glucose cotransporter-2 inhibitors treatment; Level B (52.9%): Vildagliptin should be considered as a part of the treatment algorithm only when the patient population is elderly, with long-standing diabetes, newly diagnosed T2DM with prior CVD, patients with obesity, or renal impairment. The majority of HCPs reported clinical benefits including a reduction in the dose of insulin (52.4%) and the number of hypoglycemic incidences (33.3%) with vildagliptin plus insulin. Conclusion: Indian clinical experts recommended the safe and neutral use of vildagliptin in patients with T2DM and CV risk and/or CVD.

show abstract

Section: Discussionsupporting

confidence: 87%

Expert viewpoint on the position of Vildagliptin in a cardiology clinic in Indian clinical settings

Das¹,

Shah²,

Warrier³

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…The clinical endpoints that physicians use to determine the optimal care of patients has changed from glycaemic control (HbA1c) to a focus on prevention of macrovascular disease, in particular the prevention of cerebrovascular, renal, and cardiac disease. 10 During this time, new agents and drug classes have become available that are effective in the prevention of these morbidities. 11,12 Diabetes landscape evolution can be classified into several time periods:…”

Section: Diabetes Treatment Landscape Progression and Evolution Towar...mentioning

confidence: 99%

Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus

2019

View full text Add to dashboard Cite

The management of adults with Type 2 diabetes mellitus (T2DM) was traditionally delivered in a single specialist setting with a focus on glycaemic control. As the treatment landscape evolved to consider the need to prevent cardiovascular disease and/or microvascular complications, so did the requirement to manage this complex multisystem condition by multiple healthcare providers in both primary care and specialist settings. This article discusses the key studies that changed the way T2DM is managed to incorporate an interdisciplinary approach to care, the principles of the multidisciplinary teams, examples of multidisciplinary teams in real-world clinical practice, and associated patient outcomes.

show abstract

“…[122] CODEN (USA): JDDTAO T2DM and their accompanying life-threatening complications, such as cardiovascular disease, nephropathy, neuropathy and retinopathy with blindness 8 .…”

Section: Introductionmentioning

confidence: 99%

“…Sulfonyl urea and meglitinides biguanides and thiazolinediones 8,19 were developed to treat DM; but were ineffective for the hyperlipidaemia associated with DM, were toxic and resistance was experienced 20 and costly for the developing world 21,22 .…”

Section: Introductionmentioning

confidence: 99%

Antiinflammatory Lupeol and Antidiabetic Compound Coexist in Ethyl Acetate and n-Hexane Extracts from Stem Bark of Anogeissus leiocarpus (African Birch Tree): The Therapeutic Advantages

Esievo,

Balogun,

Wassagwa

et al. 2024

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Objectives: Anogeissus leiocarpus stem bark is endowed with numerous antidiabetic properties, such as its prognostic value, treatment of organic damages, dyslipidaemia and enhancement of haematopoiesis. In addition to its antioxidant activity on oxidative stress, it accelerated wound healing and has a wide range of safety value. From the purification of its compounds to the points of crystallization it became necessary to analyse the structures for an insight into its mechanisms of actions. Design: Ethanolic extracts were partitioned with ethyl acetate, onto column chromatography packed with silica gel (70-230 mesh) mixed with 95% n-hexane and 5% ethyl acetate; concentrated fractions were loaded onto silica gel-coated thin layer chromatographic plate. Different compounds were observed under UV-light fluorescence and sprayed with sulfuric acid. Similar fractions were pooled, purified to crystals for Nuclear Magnetic Resonance structural analysis. Results: Nuclear Magnetic Resonance revealed fraction A is Lupeol, a pentacyclic triterpene anti-inflammatory compound. Conclusion: Lupeol in the crude ethanolic extract is significant in inflammatory pain of diabetes. Keywords: Lupeol, Anti-inflammatory, Anogeissus leiocarpus, Purified extract, inflammatory pain, Diabetes mellitus.

show abstract

Update on Management of Type 2 Diabetes for Cardiologists

Cited by 11 publications

References 33 publications

Expert viewpoint on the position of Vildagliptin in a cardiology clinic in Indian clinical settings

Expert viewpoint on the position of Vildagliptin in a cardiology clinic in Indian clinical settings

Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus

Antiinflammatory Lupeol and Antidiabetic Compound Coexist in Ethyl Acetate and n-Hexane Extracts from Stem Bark of Anogeissus leiocarpus (African Birch Tree): The Therapeutic Advantages

Contact Info

Product

Resources

About